Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Tuznue
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2020
The partnership includes the exclusive rights for Teva Israel to commercialize Tuznue™ (trastuzumab) in Israel, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing pharmaceutical products to market.